Correspondence on: 'SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy' by Zhao et al doi:10.1136/ard-2023-225248Lupus NephritisLupus Erythematosus, SystemicAutoimmune DiseasesAnnals of the Rheumatic DiseasesMaria José SolerConxita Jacobs Cachá...
Introduction:Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to improve cardiorenal outcomes among patients with and without diabetes mellitus.#Hypothesis:We aimed to investigate their impact on the risk of acute kidney injury (AKI) and major adverse cardiac events (MACE) after ...
SGLT2 inhibitors improve mitochondrial function. SGLT2 inhibitors activate the AMPK/PGC-1α signalling pathway, thereby increasing PGC-1α-regulated NRF-1 expression, which increases mtTFA expression and further promotes mitochondrial biogenesis. PGC-1α can also inhibit Drp1-induced mitochondrial fission ...
With multiple benefits proven in often overlapping diseases, SGLT2 inhibitors are now important tools for both general practitioners and specialists. But consistent implementation in heart failure remains a challenge, and it can be difficult to know which provider should initiate therapy in appropriate p...
sglt2 inhibitortype 2 diabetes mellitusIntroduction: Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are recommended after metformin for a large spectrum of patients with type 2 diabetes, because of a favorable benefit/risk profile despite a variety of adverse events. Areas covered: This ...
Sodium-glucose cotransporter 2 (SGLT2), which is specifically expressed on the apical side of proximal tubular cells, is involved in the reabsorption of most of the glucose filtered by the glomeruli, and its inhibitors are gaining publicity as potent antihyperglycemic drugs. In some clinical trials...
SGLT2 inhibitors improve mitochondrial function. SGLT2 inhibitors activate the AMPK/PGC-1α signalling pathway, thereby increasing PGC-1α-regulated NRF-1 expression, which increases mtTFA expression and further promotes mitochondrial biogenesis. PGC-1α can also inhibit Drp1-induced mitochondrial fission...
Recent randomized trials demonstrating the beneficial effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in type 2 diabetes suggest that early reductions in eGFR upon initiation of SGLT2i therapy are associated with improved renal outcomes. M
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control contained herein will advance the current understanding regarding the pleiotropic effects of SGLT2 inhibitors, while promoting future research in the field.Takat... TIH Takata - Current drug ...
Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis Purpose: Numerous clinical studies have explored sodium鈥揼lucose cotransporter 2 inhibitor (SGLT2i) in patients with chronic heart failure (CHF), with or ... J Chen...